[2] Eidne KA，Flanagan CA，Harris NS, et al. Gonadotropin-releasing hormone(GnrH)-binding sites in human breast cancer cell lines and inhibitory effects of GnrH antagonists[J]. J Clin Endocrinol Metab，1987，64(3): 425-432.
[2] Sealfon S，Weistein H，Miller r. Molecular mechanisms of ligand interaction with the gonadotropin releasing hormone receptor[J]. Endocr rev, 1997, 18(2): 180-205.
[3] 向梅，向均，马燕，等. LHrH-PE40 与宫颈癌组织结合特性的研 究[J]. 中国生物制品学杂志，2 006，1 9(2): 169-170.
[4] Gong SL，Zhao G，Zhu P，et al. Ability of Luteinizing releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHrH receptor on human liver cancer cells[J]. World J Gastroenterol, 2004，1 0(19): 2870-2873.
[5] FAst C，Duwe F，Hellriegel M，et al. Targeted chemotherapy for triple-negative breast cancers via LHrH receptor[J]. Oncol rep, 2011，2 5(5): 1481-1487.
[6] Wen S，Schwarz Jr，Niculescu D, et al. Functional characterization of genetically labeled gonadotropes[J]. Endocrinology，2008，149 (6): 2701-2711.
[7] Maria Comaru-Schally A，Schally AV. rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LHrH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions[J]. Adv Drug Deliv rev，1997, 28(1): 157-169.
[8] Emons G，Grundker C，Gunther Ar, et al. GnrH antagonists in the treatment of gynecological and breast cancers[J]. Endocr relat Cancer，2003, 10(2): 291-299.